Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-23T02:37:26.580Z Has data issue: false hasContentIssue false

Prolactine borderline, a case report

Published online by Cambridge University Press:  23 March 2020

N. Salgado*
Affiliation:
Hospital Dr. Rodriguez Lafora, Psiquiatria, Madrid, Spain
B. Macias
Affiliation:
Hospital Dr. Rodriguez Lafora, Psiquiatria, Madrid, Spain
S. Benavente
Affiliation:
Hospital Universitario 12 de Octubre, Psiquiatria, Madrid, Spain
R. Ruiz
Affiliation:
Hospital Dr. Rodriguez Lafora, Psiquiatria, Madrid, Spain
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

It is known that antipsychotic drugs can increase prolactinaemia, we report a case in which the use of aripiprazole after treatment with paliperidone helped regaining normality levels.

Case report

During treatment with PALiperidone12 mg/day the patient, a 27-year-old female diagnosed with borderline personality disorder, developed hyperprolactinaemia with galactorrhea and menstrual disorders. During hospitalization, aripiprazole is introduced while paliperidone is progressively decreased. Antipsychotic were prescribed because delusions of reference and auditory pseudo-hallucinations arose suddenly in a woman without history of previous psychotic breaks. Before treatment with aripiprazole, prolactinaemia was 156,96 ng/mL (pregnancy test was negative) and after stopping, paliperidone was 23,60 ng/mL.

Discussion

If hyperprolactinaemia symptoms appeared (galactorrhea…), aripiprazole is a good option if antipsychotic treatment is required. In this case, paliperidone was decreased slowly, while aripiprazole was increased, until minimum effective dose was reached.

Conclusions

Hyperprolactinaemia is a common side effect in antipsychotic treatments and if symptoms appeared aripiprazole is a good option.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1330
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.